0001415889-21-002991.txt : 20210614 0001415889-21-002991.hdr.sgml : 20210614 20210614164754 ACCESSION NUMBER: 0001415889-21-002991 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210610 FILED AS OF DATE: 20210614 DATE AS OF CHANGE: 20210614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Xencor Inc CENTRAL INDEX KEY: 0001326732 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38793 FILM NUMBER: 211015148 BUSINESS ADDRESS: STREET 1: 111 WEST LEMON AVE CITY: MONROVIA STATE: CA ZIP: 91016 BUSINESS PHONE: 626-305-5900 MAIL ADDRESS: STREET 1: 111 WEST LEMON AVE CITY: MONROVIA STATE: CA ZIP: 91016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inmune Bio, Inc. CENTRAL INDEX KEY: 0001711754 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475205835 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1200 PROSPECT STREET STREET 2: SUITE 525 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 8589643720 MAIL ADDRESS: STREET 1: 1200 PROSPECT STREET STREET 2: SUITE 525 CITY: LA JOLLA STATE: CA ZIP: 92037 4 1 form4-06142021_010635.xml X0306 4 2021-06-10 0001711754 Inmune Bio, Inc. INMB 0001326732 Xencor Inc 111 W. LEMON AVE MONROVIA CA 91016 false false true false Common Stock 2021-06-10 4 J 0 192532 17.14 A 1777532 D On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021. /s/ John J. Kuch 2021-06-14